Recap: Blueprint Medicines Q4 Earnings
Recap: Blueprint Medicines Q4 Earnings
Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimate of ($1.62).
Revenue of $34,107,000 decreased by 33.82% from the same period last year, which beat the estimate of $29,240,000.
Looking Ahead
Blueprint Medicines hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Feb 17, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/shp6w5zy
Recent Stock Performance
Company's 52-week high was at $125.61
52-week low: $43.29
Price action over last quarter: down 8.88%
Company Description
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Shares of Blueprint Medicines (NASDAQ:BPMC) were unchanged after the company reported Q4 results.
的股份蓝图药品(纳斯达克：BPMC)在公司公布第四季度业绩后保持不变。
Quarterly Results
季度业绩
Earnings per share fell 13.33% over the past year to ($1.53), which beat the estimate of ($1.62).
过去一年每股获利下滑13.33%至(1.53美元)，超过预估的(1.62美元)。
Revenue of $34,107,000 decreased by 33.82% from the same period last year, which beat the estimate of $29,240,000.
营收为34,107,000美元，较去年同期下降33.82%，超过预期的29,240,000美元。
Looking Ahead
展望未来
Blueprint Medicines hasn't issued any earnings guidance for the time being.
Blueprint Medicines暂时没有发布任何盈利指引。
Revenue guidance hasn't been issued by the company for now.
该公司目前尚未发布营收指引。
How To Listen To The Conference Call
如何收听电话会议
Date: Feb 17, 2021
日期：2021年2月17日
Time: 08:30 AM
时间：上午8时30分
ET Webcast URL: https://edge.media-server.com/mmc/p/shp6w5zy
Recent Stock Performance
近期股市表现
Company's 52-week high was at $125.61
该公司52周高点为125.61美元
52-week low: $43.29
52周低点：43.29美元
Price action over last quarter: down 8.88%
上季度价格走势：下跌8.88%
Company Description
公司描述
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.
Blueprint Medicines Corp是一家生物制药公司。它的重点是改善由异常激酶激活引起的疾病患者的生活。该公司已经开发出一种治疗癌症和一种罕见遗传病的小分子药物流水线。它的候选药物BLU-285针对KIT Exon 17突变体和PDGFRA D842V，这是一种异常活跃的受体酪氨酸激酶突变体，是癌症和增殖性疾病的驱动因素。它的另一个候选药物是用于晚期肝细胞癌的BLU 554，以及用于Ret突变、融合和预测耐药突变的BLU-667。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧